Publication | Open Access
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
1.2K
Citations
38
References
2017
Year
Among adults with multiple myeloma, RVD therapy plus transplantation was associated with significantly longer progression-free survival than RVD therapy alone, but overall survival did not differ significantly between the two approaches. (Supported by Celgene and others; IFM 2009 Study ClinicalTrials.gov number, NCT01191060 .).
| Year | Citations | |
|---|---|---|
Page 1
Page 1